These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22588607)

  • 1. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
    Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M
    Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
    Oh J; Lee S; Lee H; Cho JY; Yoon SH; Jang IJ; Yu KS; Lim KS
    PLoS One; 2017; 12(4):e0176320. PubMed ID: 28437488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.
    Tarkiainen EK; Holmberg MT; Tornio A; Neuvonen M; Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacol Ther; 2015 Jun; 97(6):650-8. PubMed ID: 25704243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alcohol on human carboxylesterase drug metabolism.
    Parker RB; Hu ZY; Meibohm B; Laizure SC
    Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
    Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M
    J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.
    Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.
    Walter Soria N; Belaus A; Galván C; Ana Pasquali M; Velez P; Del Carmen Montes C; Beltramo DM
    Genet Test Mol Biomarkers; 2010 Dec; 14(6):749-51. PubMed ID: 20858053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
    Hu ZY; Edginton AN; Laizure SC; Parker RB
    Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.
    Zhu HJ; Markowitz JS
    Drug Metab Dispos; 2009 Feb; 37(2):264-7. PubMed ID: 19022936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.
    Tarkiainen EK; Tornio A; Holmberg MT; Launiainen T; Neuvonen PJ; Backman JT; Niemi M
    Br J Clin Pharmacol; 2015 Nov; 80(5):1131-8. PubMed ID: 25919042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.
    Brewster M; Smith JR; Dutkowski R; Robson R
    Vaccine; 2006 Nov; 24(44-46):6660-3. PubMed ID: 16797800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.
    Jang K; Kim MK; Oh J; Lee S; Cho JY; Yu KS; Choi TK; Lee SH; Lim KS
    Drug Des Devel Ther; 2017; 11():705-711. PubMed ID: 28331290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
    Davies BE
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.
    Suzaki Y; Uemura N; Takada M; Ohyama T; Itohda A; Morimoto T; Imai H; Hamasaki H; Inano A; Hosokawa M; Tateishi M; Ohashi K
    Eur J Clin Pharmacol; 2013 Jan; 69(1):21-30. PubMed ID: 22673926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.